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Abstract
Since its identification in 1989, hepatitis C virus (HCV) 
has emerged as a worldwide health problem with roughly 
185 million chronic infections, representing individuals 
at high risk of developing cirrhosis and liver cancer. In 
addition to being a frequent cause of morbidity and 
mortality due to liver disease, HCV has emerged as an 
important trigger of lymphoproliferative disorders, owing 
to its lymphotropism, and of a wide spectrum of extra-
hepatic manifestations (HCV-EHMs) affecting different 
organ systems. The most frequently observed HCV-EHMs 
include mixed cryoglobulinemia and cryoglobulinemic 
vasculitis, B-cell non-Hodgkin’s lymphoma, nephropathies, 
thyreopathies, type 2 diabetes mellitus, cardiovascular 
diseases, and several neurological conditions. In 
addition, neuropsychiatric disorders and neurocognitive 
dysfunction are reported in nearly 50% of patients with 
chronic HCV infection, which are independent of the 
severity of liver disease or HCV replication rates. Fatigue, 
sleep disturbance, depression and reduced quality 
of life are commonly associated with neurocognitive 
alterations in patients with non-cirrhotic chronic HCV 
infection, regardless of the stage of liver fibrosis and 
the infecting genotype. These manifestations, which are 
the topic of this review, typically occur in the absence 
of structural brain damage or signal abnormalities on 
conventional brain magnetic resonance imaging (MRI), 
although metabolic and microstructural changes can 
be detected by in vivo  proton magnetic resonance 
spectroscopy, perfusion-weighted and diffusion tensor 
world population, corresponding to roughly 185 million 
people, is chronically infected. However, infection rates 
are highly variable across different geographic areas[2]. 
Of the six major HCV genotypes (gt), gt-1 is the most 
common worldwide, with subtype 1b being prevalent 
in Europe and subtype 1a in the United States. In 
intravenous drug users, gt-3a is more frequently 
detected in Europe and gt-2 in the Mediterranean area. 
Genotypes 5 and 6 are rare, whereas gt-4 occurs in 
over 20% of the infected Egyptians. 
Chronic HCV infection progresses to liver cirrhosis 
in 10% to 40% of the patients (this condition is the 
leading indication for liver transplantation) and liver 
cancer (i.e., hepatocellular carcinoma, HCC) in 1% 
to 5% per year. The annual mortality rate has been 
calculated to be roughly 4% of patients with cirrhosis 
and 30% of those with HCC. 
HCV-related neurological dysfunction is frequently 
observed either at cirrhotic or pre-cirrhotic stages. 
A major central nervous system (CNS) complication 
observed in patients with cirrhosis of differing 
aetiology, including those with HCV infection, is 
hepatic encephalopathy (HE), a potentially reversible 
neuropsychiatric syndrome, with symptoms ranging 
from clinically undetectable neuropsychological 
disturbances (minimal HE) to severe impairment 
of attention and arousal (overt HE). In addition, a 
large number of neurological complications occur in 
patients with chronic HCV infection independently of 
liver disease, including metabolic, inflammatory and 
autoimmune conditions affecting the CNS, as well as 
the peripheral nervous system and muscles[3,4].
CONCEPT OF HCV SYNDROME
HCV has been confirmed as both a hepatotropic and 
lymphotropic virus. Consequently, the liver is not the 
only target of HCV infection, so that several other 
organs and tissues are also likely to be involved[5].
The term “HCV syndrome” was coined to include 
both hepatic and extra-hepatic manifestations of 
HCV infection[6,7]. One major extra-hepatic disorder 
associated with HCV is mixed cryoglobulinemia, which, 
in a minority of patients, results in clinically overt 
cryoglobulinemic vasculitis (CV)[8]. In agreement with 
the experience of other research groups, our data 
indicate that 90% or more of CV patients are in fact 
anti-HCV/HCV RNA positive. Figure 1 summarizes 
the major extra-hepatic manifestations that have 
been diagnosed, based on our own experience[9], in 
chronically infected HCV patients, with or without 
mixed cryoglobulinemia. As the figure illustrates, the 
most convincing associations of chronic HCV infection 
are with subsets of B-cell non-Hodgkin lymphoma 
(B-NHL), membranous or membrano-proliferative 
glomerulonephritis, IgM monoclonal gammopathy 
of undetermined significance (MGUS), peripheral 
neuropathy, and CNS disorders. 
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MRI, and neurophysiological tests of cognitive processing. 
Several lines of evidence, including comparative and 
longitudinal neuropsychological assessments in patients 
achieving spontaneous or treatment-induced viral 
clearance, support a major pathogenic role for HCV in 
neuropsychiatric and neurocognitive disorders.
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Core tip: Neurocognitive dysfunction, sleep disturbance, 
depression, fatigue and reduced quality of life are 
common manifestations of chronic hepatitis C virus 
(HCV) infection. Neuropsychological performance is 
impaired in HCV patients, in the absence of structural 
brain alterations on conventional magnetic resonance 
imaging (MRI). Brain metabolic and microstructural 
changes are easily detected by in vivo  proton magnetic 
resonance spectroscopy and perfusion-weighted/
diffusion tensor MRI, enabling detection of brain 
dysfunction in clinically asymptomatic subjects. The 
regional distribution of metabolic changes indicates an 
exclusive involvement of telencephalic areas, but not 
the diencephalon or brainstem. HCV is likely to play a 
major pathogenic role in these disorders. 
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INTRODUCTION
Previously designated as non-A non-B hepatitis, the 
hepatitis C virus (HCV) was unequivocally recognized 
and established as a distinct virus after its isolation in 
1989[1]. In the following 26 years, HCV has been the 
subject of extensive research which has expanded our 
knowledge of the biomolecular and clinical features 
of HCV infection tremendously, and has paved the 
way for the introduction of newly synthesized, highly 
effective, direct-acting antiviral agents that are making 
eradication of the virus an achievable goal in nearly all 
chronically infected patients. 
Acute HCV infection is usually asymptomatic and 
able to resolve spontaneously in as high as 90% of 
cases, and thus remains undiagnosed in the majority 
of patients. Even so, progression to chronic infection 
occurs frequently. Thus, HCV represents a worldwide 
health problem considering that at least 3% of the 
PaTHOgENETIC IMPlICaTIONS
The role played by HCV in the pathogenesis of the 
largely autoimmune and neoplastic diseases remains 
undefined, but a reasonable hypothesis is that HCV 
infection is an important component of a polyfactorial 
process in which multiple genetic and environmental 
cofactors are involved to a variable extent. The long-
term observation of cohorts of HCV-positive patients 
indicates that many of them develop a complex and 
progressively more severe spectrum of HCV-related 
disorders, advancing from mild and often limited 
features, to systemic and more severe complications 
that may include HCC, B-NHL and possibly other 
neoplastic histotypes[10].
Studies of the biology of HCV have been hampered 
by the fact that for many years chimpanzees were the 
only non-human in vivo models, and there was an 
unmet need for the development of in vitro experimental 
models. More recently though, researchers determined 
how to grow infectious HCV particles in cell cultures, 
which has resulted in a better understanding of the 
virus-host interactions enhancing virus propagation. 
Furthermore, small animal models permissive to HCV 
have been established, which now make it possible 
to investigate new antiviral agents and in the future, 
potential vaccine preparations[11]. 
Recognized pathogenetic mechanisms in several 
HCV-related neurological disorders have in common an 
upregulated host immune response accompanied by 
production of autoantibodies, immune complexes, and 
cryoglobulins. However, alternative mechanisms have 
been proposed for the neurocognitive impairment and 
neuropsychological changes observed in HCV patients. 
The isolation of HCV RNA in microglial cells and 
astrocytes and evidence that brain endothelial cells 
are permissive for HCV entry and replication suggest 
an independent life and a pathogenic role of the virus 
in the brain[12]. These findings are at variance with 
the detection of nonreplicative HCV RNA in epineurial 
macrophages, but not in the “endoneurial microglia”, 
of nerve biopsies of patients with HCV infection and 
peripheral neuropathy[13,14]. 
Although the clinical spectrum of HCV syndrome 
has been expanded, the exact pathophysiological 
mechanisms of cognitive impairment, neuropsychiatric 
disorders, and sleep disturbance remain poorly 
understood. Efforts to elucidate molecular pathways 
have provided results suggesting a pathogenic role for 
the virus itself, iatrogenic factors, and inflammatory 
cytokines in distinct neuropsychiatric conditions. 
Therefore, the detection of defective central sero-
toninergic and dopaminergic neurotransmission in 
some HCV patients with neuropsychiatric symptoms 
and mild or no liver disease has suggested a possible 
role for HCV in inducing dysfunction in selective 
aminergic systems[15]. On the other hand, in patients 
under treatment with interferon (IFN), the occurrence 
of depression has been correlated with depletion 
of platelet serotonin, an effect also expected within 
the CNS, due to the effectiveness of antidepressant 
drugs that inhibit serotonin reuptake[16,17]. Other 
proposed mechanisms for dysfunction of the CNS and 
the neuroendocrine system include cytotoxic effects 
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Figure 1  Summary of major extra-hepatic manifestations observed in patients with chronic hepatitis C virus infection. Percentages of patients are 
represented in graphic form. The presence or absence of cryoglobulinemia is indicated by white and black, respectively. The most convincing associations of 
chronic hepatitis C virus (HCV) infection are with subsets of B-cell non-Hodgkin lymphoma (B-NHL), membranous or membrano-proliferative glomerulonephritis, IgM 
monoclonal gammopathy of undetermined significance (MGUS), peripheral neuropathy, and central nervous system (CNS) disorders.
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were documented in a study involving 37 HCV patients 
without significant liver disease or other relevant 
comorbidities. In these individuals, 1H MRS revealed 
increases in choline and decreases in NAA in the 
centrum semiovale, as well as increases in creatine, 
a marker of astrocytic gliosis and microglia activation, 
in basal ganglia[24]. Increased levels of creatine were 
also detected in the basal ganglia of HCV patients with 
impaired attention and working memory in another 
study; unexpectedly, increased concentrations of NAA 
plus N-acetyl-aspartyl-glutamate, possible markers 
of on-going repair and neuroprotective mechanisms, 
were also found in these patients[25]. More recently, 
decreases in NAA/creatine ratios in the fronto-parietal 
WM, in the absence of other metabolic changes, 
were found in 15 patients with mild liver disease, 
diminished visual concentration endurance and 
unaffected executive function[26]. These alterations 
were coupled with increased perfusion of basal ganglia 
and reduced perfusion of left frontal cortex, bilateral 
temporoparietal cortices, and posterior cingulate 
gyrus[27]. Furthermore, increased myoinositol in 
bilateral frontal WM and decreased levels of NAA in 
parietal WM without changes in basal ganglia were 
documented in a cohort of HCV treatment-naïve 
patients with reduced psychomotor speed and verbal 
fluency. These patients also showed microstructural 
brain pathology in the striatum, external capsule, and 
fronto-occipital fasciculus by diffusion tensor MRI[28]. 
Taken together, the variability observed across different 
studies likely reflects the use of different psychometric 
scales and heterogeneity among recruited patients. 
Results of studies addressing the quantification of 
brain metabolite concentrations in HCV patients with 
neuropsychological and neurocognitive dysfunction are 
shown in Figure 2. Despite a number of limitations, 
these studies demonstrate that chronic HCV infection 
is associated with significant brain metabolic 
alterations as a result of activation and proliferation 
of glial cells (including astrocytes, microglia, and 
monocyte/macrophages) and increased turnover of 
myelin membranes. The regional distribution of 1H 
MRS abnormalities suggests that only cortical and 
subcortical telencephalic areas, but not the thalamus 
or posterior fossa structures, are involved in HCV-AND. 
These findings are in agreement with results of 
neuropathological studies in human immunodeficiency 
virus (HIV)-HCV co-infected individuals, demonstrating 
the presence of HCV RNA in the frontal cortex, basal 
ganglia, and subcortical white matter, but not in the 
thalamus, cerebellum, and brainstem. In addition, HCV 
NS5A and NS3 proteins, as well as the core antigen, 
were found in astrocytes and macrophage/microglial 
cells[29]. These findings are relevant, in view of the 
evidence that the core protein may trigger and 
support a neurodegenerative cascade through the 
activation of ERK/STAT3 pathway[30]. Studies using 
ligands that bind serotonin and dopamine transporters 
have revealed a decreased density of serotonin 
induced by cytokines released during systemic or brain 
immune activation[18,19].
COgNITIVE IMPaIRMENT
Altered neuropsychological performance and neuro-
cognitive impairment are frequently reported in 
patients with chronic HCV infection, often at stages 
characterized as having a lack of significant liver 
fibrosis and cirrhosis. These alterations typically occur 
independently of HCV genotype and in the absence 
of structural brain damage or signal abnormalities 
on conventional brain magnetic resonance imaging 
(MRI). Over the last few years, a number of factors, 
including associated comorbidities, alcohol misuse, 
substance abuse, interferon treatment, and HCV 
itself, have been investigated to assess their role 
as deteriorating or causative contributors to HCV-
associated neurocognitive disorder (HCV-AND). 
Available data suggest that HCV-AND is unrelated to 
advanced liver disease, and therefore, the nature of 
this condition is distinct from the potentially reversible 
neuropsychological/neurophysiological complications 
observed in individuals with minimal HE, i.e., with 
biopsy-proven compensated cirrhosis or portal-
systemic encephalopathy. Unravelling the contribution 
of different factors to cognitive dysfunction and 
elucidating the pathogenic role of HCV represent 
issues of major importance for making personalized 
treatment options available. Emerging lines of 
evidence suggest that the profile of neuropsychological 
dysfunction in HCV-infected patients is characterized by 
impairment in executive function, sustained attention, 
working memory, verbal learning and verbal recall. 
Conversely, the neuropsychological complex observed 
in minimal HE includes impairment in psychomotor 
speed, selective attention, visuoconstructive function 
and executive function. Forton et al[20], using in vivo 
proton magnetic resonance spectroscopy (1H MRS), 
first reported elevated choline/creatine ratios in basal 
ganglia and frontal white matter (WM) of HCV-infected 
patients with mild liver disease, but not in patients with 
hepatitis B virus (HBV) infection. Subsequently, these 
alterations were correlated with impaired concentration 
and working memory in a group of patients with active 
viral replication[21], whereas the cognitive performance 
of patients who had achieved HCV clearance was 
equivalent to that of controls. Intriguingly, metabolic 
changes detected by 1H MRS in HCV patients were 
different from abnormalities previously associated with 
minimal HE, which were characterized by reduced 
choline/creatine ratios[22]. The occurrence of significant 
deficits in executive function and attention, with 
worse performance in patients complaining of fatigue, 
has been reported in HCV patients with normal liver 
function. This neuropsychological profile was correlated 
with a decrease in N-acetylaspartate (NAA)/creatine 
ratios in the cerebral cortex[23]. Conversely, only slight 
attention deficit and impairment of verbal learning 
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and dopamine nerve terminals on single-photon-
emission computed tomography in HCV patients with 
neuropsychiatric disorders and cognitive impairment, 
even in the absence of significant liver disease. 
Moreover, images obtained through positron-emission 
tomography with the use of fluorodeoxyglucose 
revealed decreased glucose metabolism in limbic, 
frontal, parietal and temporal cortices[15,31,32]. Earlier 
studies, employing neurophysiological tests of cognitive 
processing, revealed delayed peak latencies and 
reduced amplitudes of P300 in HCV patients compared 
to healthy subjects, thus providing a potential and 
sensitive neurophysiological measure of subclinical 
cognitive impairment[33]. 
The characterization of neuropsychological/
cognitive dysfunction in HCV patients has been the 
subject of several studies. Defects in verbal recall 
and working memory were found in one-third of HCV 
patients, including individuals with advanced liver 
fibrosis, cirrhosis, and a history of alcohol misuse 
and/or intravenous drug abuse. In contrast to earlier 
reports, cognitive performance was not affected by the 
degree of fibrosis[34]. Impairment of verbal learning 
and memory was detected in a cohort of HCV and HBV 
patients, including patients with cirrhosis, as compared 
to healthy controls[35], whereas verbal learning, 
auditory attention, and reasoning/mental flexibility 
were affected in a cohort of 24 non-cirrhotic HCV 
patients with a negative history for medical/psychiatric 
comorbidities, and drug and/or alcohol abuse[36]. 
More recently, the study of a small and well-selected 
cohort of homogeneous state-infected, treatment-
naïve patients with mild liver involvement and a similar 
history of iatrogenic HCV exposure, showed that half of 
HCV RNA-positive patients had alterations in memory, 
sustained attention, and delayed auditory recognition, 
as compared to HCV RNA-negative subjects who 
had spontaneous viral clearance[37]. The effect of 
successful anti-HCV treatment on neurocognitive 
measures was recently investigated in a longitudinal 
multicentre study involving a relatively large number 
of HCV patients, 15% of whom had cirrhosis. Long-
term evaluation at 12 mo or more following treatment 
showed a significant improvement in vigilance and 
working memory in patients who had achieved 
sustained virological response (SVR), but not in non-
responders[38]. 
PSYCHIaTRIC DISTURBaNCES
Sexual dysfunction, emotional distress and psychiatric 
disturbances are frequently described in HCV-infected 
patients. People with HCV infection have a higher risk 
for depression, anxiety, somatization, compulsiveness, 
insecurity, aggression/hostility, phobic anxiety, and 
psychosis[39]. Although major psychiatric co-morbidities, 
concomitant or previous substance abuse, and the 
psychological consequences of having a chronic life-
threatening illness may account for most of these 
manifestations, several studies have indicated a 
primary role for HCV. Based on DSM-IV criteria, 28% 
of chronically HCV-infected individuals experience 
depression, which makes it difficult for them to adhere to 
therapy[40,41]. Major depressive disorder[42] and recurrent 
brief episodes of depression unrelated to interferon 
treatment have been reported[43]. Nevertheless, 
the prevalence of psychiatric symptoms is probably 
underestimated in routine clinical examination[44], even 
though psychiatric screening, accurate diagnosis, and 
confirmatory evaluation by validated measures are 
strictly required[45]. Depression, anxiety and fatigue 
are among the most common adverse events in 
IFN/ribavirin treatment, and their cumulative incidence 
seems to increase during IFN treatment, but returns to 
baseline values following completion of therapy[46]. 
No major risk factors for treatment-induced 
psychiatric symptoms have been identified as of 
yet[47]. While the presence of depression at baseline 
can be predictive of increased psychiatric burden and 
early treatment discontinuation, no apparent impact 
on the achievement of SVR in patients completing 
treatment has been reported[48,49]. Failure to clear 
HCV-RNA has however been associated with IFN-
induced depression[44,50], and in these cases, serotonin-
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Figure 2  Quantification and localization of brain metabolite concentrations in hepatitis C virus patients exhibiting neuropsychological and neurocognitive 
dysfunction. The regional distribution of proton magnetic resonance spectroscopy (1H MRS) abnormalities suggests that only cortical and subcortical telencephalic 
areas, but not the thalamus or posterior fossa structures, are involved in hepatitis C virus (HCV)-associated neurocognitive disorder (HCV-AND).
Basal ganglia
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norepinephrine reuptake inhibitors, bupropion and 
modafinil, may improve affective and neurovegetative 
symptoms of depression[51]. The efficacy of pre-
emptive antidepressant therapy has been questioned 
in some studies[52], with the exception of patients 
with pre-existing subclinical depressive mood, mild 
cognitive disturbances, sadness, and reduced sleep[53]. 
In addition to depression, HCV is associated with 
social marginalization, impairment of intimate and 
family relationships, reduced sense of well-being, 
anger, inappropriate coping strategies, and stigma[51]. 
The pathogenesis of HCV-related neuropsychiatric 
symptoms is poorly understood and it still remains to 
be determined whether the occurrence of depression is 
a risk factor or a consequence of the infection. 
While psychological and social factors are of 
primary importance, the evidence that depression 
is less frequently observed in HBV-infected patients 
treated with IFN compared to those with HCV infection 
suggests a relevant role of the virus itself in the 
development of neuropsychiatric symptoms[54].
FaTIgUE
Central or cognitive fatigue is a subjective lack of 
energy remaining after rest, which is perceived 
as a sensation of physical and mental exhaustion, 
and is accompanied by a lack of motivation and 
difficulty in initiating and completing wilful actions. 
Severe fatigue is frequently associated with impaired 
cognitive function, with defects in concentration, 
attention tasks, and memory on neuropsychological 
testing. Irrespective of the severity of liver disease 
or viral replication rate, between 53% and 80% of 
HCV-infected patients complain of fatigue, often in 
conjunction with joint pain, restless leg syndrome, 
mood alterations, and headache[55]. Intriguingly, fatigue 
is worse in HCV-infected patients than in patients with 
comparable liver dysfunction of other aetiologies[56,57], 
and improves after antiviral treatment in the majority 
of patients. However, persistence of fatigue is observed 
in roughly one third of patients despite the decrease in 
viral load[58]. 
The association between HCV infection and fatigue 
has been questioned in earlier studies comparing 
HCV-infected patients with healthy blood donors[59], 
and also in studies reporting the lack of a prevalence 
of HCV infection among patients with chronic fatigue 
syndrome[60,61]. However, the latter condition, which 
differs from chronic fatigue, is a clinically defined 
complex disorder coupling disabling fatigue with 
neuropsychiatric symptoms, sore throat, muscle 
or joint pain, cervical or axillary lymphadenopathy, 
sleep disturbance, headache, and post-exertional 
exacerbation of malaise. In a cross-sectional 
observational study, 130 HCV-infected patients, 34% 
with cirrhosis, and 61 healthy controls completed a 
questionnaire to assess health-related quality of life 
(HRQL); 95 HCV patients also completed a fatigue 
questionnaire[62]. Chronic fatigue (defined as fatigue 
persisting for ≥ 6 mo) and chronic fatigue syndrome 
occurred in 71% and 27%, respectively, of HCV 
patients compared to 25% and 11% in the control 
population. Nevertheless, while more HCV patients 
reported chronic fatigue, the severity of fatigue 
experienced was similar between the two populations. 
Establishing the causes of fatigue in patients with 
chronic HCV infection is difficult, although comorbid 
neuropsychiatric symptoms, liver fibrosis, and HCV 
neuroinvasion have been considered in several 
studies. However, while severe fatigue is generally 
an indication for antiviral treatment, “iatrogenic 
fatigue” is commonly encountered during interferon 
therapy, often leading to premature interruption of 
the treatment. A recent study addressed the effect 
of pegylated-INF/ribavirin treatment on fatigue in a 
cohort of patients with chronic HCV infection. At 24 
wk after completion of treatment, the proportion of 
patients experiencing fatigue shifted from a baseline 
value of 53% to 33% in the group achieving SVR, 
with a median decrease at the visual analogue scale 
from 27 mm to 13 mm. Conversely, a non-significant 
decrease for the presence and the severity of fatigue 
was observed among non-responders[63]. 
SlEEP DISORDERS
Sleep has been defined as a behaviour which can be 
measured according to five dimensions, including 
duration, efficiency, timing, alertness, and satisfaction[64]. 
The assessment of the aforementioned dimensions 
represents a valuable indicator of sleep health. Sleep 
disturbance has a negative impact on innate immunity, 
impairs the response to infectious agent and vaccines, 
and is associated with increased susceptibility to acute 
infections and severity of symptoms[65]. In addition, the 
reported higher prevalence of altered sleep patterns 
in patients with acute and chronic infections, often 
occurring in conjunction with pain and fatigue in the 
setting of the so-called “sickness behaviour”, reinforces 
the notion that the talk between the immune system 
and the brain is of great importance in regulating sleep 
architecture and other aspects of this behaviour. 
Sleep disturbance with disordered circadian 
rhythm and reversal of day and night cycle has been 
frequently reported in patients with overt HE. In 
addition, abnormal sleep patterns have been detected 
in 50% of cirrhotic patients with minimal HE, as well 
as in those with non-cirrhotic chronic liver disease. 
To date, little attention has been devoted to sleep 
disturbance in chronic HCV-infected patients in spite 
of the frequent occurrence of complaints in sleep 
satisfaction/quality, a subjective judgement of sleep 
as good or poor. In a recent study, self-report sleep 
scales assessing quality, latency, duration, efficiency, 
and daytime dysfunction, in addition to sleep diaries 
and wrist actigraphy (as a measure of nocturnal 
activity and sleep-wake patterns), were combined to 
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examine a cohort of non-cirrhotic HCV patients with 
mild hepatic disease[66]. Not surprisingly, HCV-infected 
patients were dissatisfied with sleep quality, and 
exhibited altered sleep patterns, increased nocturnal 
activity, and poorer sleep efficiency, regardless of 
their individual viremic state. However, no alterations 
in the 24-h physical activity level were observed, 
and no correlation was found between fatigue and 
nocturnal activity. These findings are in contrast to 
the sleep disturbance observed in cirrhotic patients, 
which is characterized by fragmentation of sleep and 
reduced 24-h activity[67]. In addition, for delayed sleep 
phase syndrome, pronounced daytime sleepiness 
and frequent awakenings were observed in patients 
with minimal HE[68]. Taken together, among extra-
hepatic manifestations of chronic HCV infection, sleep 
disruption entails a significant burden, and negatively 
impacts mood alterations[69], quality of life, and 
possibly fatigue. Further research is needed to clarify 
the pathophysiological mechanisms responsible for 
alterations in the circadian clock. 
QUalITY OF lIFE
Quality of life can be defined as overall satisfaction 
with life, referring to wellbeing within the functional 
domain assessment of physical and mental health 
and social functioning. Chronic medical conditions are 
typically associated with a reduced quality of life as 
reported by patients, although measurement tools of 
such aspects have obvious limitations. Existing self-
reporting questionnaires generate different scores 
according to different categories, such as general and 
mental health, social and physical functioning, pain, 
vitality, and impact of the disease[70]. There are no 
quality of life assessment scales specifically developed 
for HCV-infected subjects. SF-36 or its short version 
(SF-12) are typically used, since these methods have 
largely demonstrated high accuracy in detecting quality 
of life impairment in a wide range of chronic diseases. 
More than half of patients with chronic HCV infection 
complain of fatigue, lassitude, impaired concentration 
and memory, which are known to interfere negatively 
with quality of life at least as much as physical 
symptoms. Patients also report a reduced quality of 
life, which is frequently independent of the severity 
of liver involvement or virus replication rate. Fatigue, 
cognitive dysfunction and mood alterations have a 
profound effect on social and physical functioning, 
thus further impacting HRQL[71]. Lower quality of 
life scores have been described in HCV subjects 
compared to HBV-infected patients and healthy 
controls[56]. Interestingly, these findings seem not to 
be exclusively related to the psychological effect of 
HCV positive status awareness, since patients who are 
unaware of the infection perform better than patients 
who know their HCV status but worse than healthy 
individuals[72]. More recent studies that assessed HRQL 
using the SF-12 questionnaire in German HCV/HBV 
positive patients and healthy controls, confirmed a 
predominant impairment on both mental and physical 
quality of life in HCV subjects despite a more evident 
liver disease in HBV ones[73-75]. Whether these data 
reflect direct viral damage or are a consequence of 
chronic inflammation is still unclear, but viral infection 
itself is an important factor contributing to reduced 
HRQL. 
SVR has been associated with an improvement 
in HRQL scores that can be due to both viral status 
and patient perception. Using the SF-36 scale, a 
comparison between HCV infected patients and 
healthy subjects revealed a lower HRQL at baseline, 
but a marked improvement was noted in patients 
responsive to IFN/antiviral treatment[76]. However, IFN 
treatment may also be associated with reduced quality 
of life, in particular during the initial phase of therapy, 
which is likely to be due to potential side effects of IFN 
injections both at physical and emotional levels[77]. 
THERaPY OF CHRONIC HCV INFECTION: 
PRESENT aND FUTURE
The combination of IFN and ribavirin no longer 
represents the therapeutic standard of care, at least 
for difficult-to-cure HCV-infected patients of gt-1 and 
gt-4[78]. The introduction of telaprevir and boceprevir 
has resulted in a higher rate of SVR, but these 
antiviral agents are being rapidly replaced by the new 
interferon-free, all-oral regimens that include direct-
acting antivirals such as sofosbuvir, daclatasvir, and 
simeprevir, with or without ribavirin. In spite of the 
high costs that currently prevent their accessibility 
to all patients who may benefit from treatment, 
several of these regimens are under intensive clinical 
investigation and have been able to induce SVR in 
90% or more of the patients, even in those with HCV 
re-infection and accelerated progression following liver 
transplant[79]. 
A careful assessment of the most appropriate 
therapeutic regimen for each specific clinical situation 
will require further multicentre trials. Additional points 
that need to be addressed include the identification of 
novel predictive factors, the adoption of new criteria 
to define the length of therapy, and the elucidation 
of resistance mechanisms that may result in the 
emergence of drug-resistant viral variants. Finally, the 
most eagerly awaited goal is the development of a 
safe and effective vaccine.
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